Around 75% of breast tumours express estrogen receptor (ER+). Endocrine therapy (ET) is a cornerstone in the treatment of both early and metastatic disease, but its effectiveness is limited by the developing of acquired resistance and more rarely by de novo resistance. Understanding the mechanisms of resistance to ET represents a challenge. Recently acquired mutations in ESR1, have been associated with resistance to aromatase inhibitor (Ai) therapy in hormone-refractory metastatic breast cancer (MBC).

Estrogen receptor mutation: a new strategy to overcome endocrine resistance

Moretti, A
Primo
;
Lupini, L;Carandina, I;Bassi, C;Lancia, F;Daniel, F;Belluomini, L;Toma, I;Bannò, E;Nisi, C;Da Ros, L;Querzoli, P;Negrini, M
Penultimo
;
Frassoldati, A
Ultimo
2017

Abstract

Around 75% of breast tumours express estrogen receptor (ER+). Endocrine therapy (ET) is a cornerstone in the treatment of both early and metastatic disease, but its effectiveness is limited by the developing of acquired resistance and more rarely by de novo resistance. Understanding the mechanisms of resistance to ET represents a challenge. Recently acquired mutations in ESR1, have been associated with resistance to aromatase inhibitor (Ai) therapy in hormone-refractory metastatic breast cancer (MBC).
2017
Breast cancer
File in questo prodotto:
File Dimensione Formato  
2017_abstract Annals of oncology.pdf

accesso aperto

Tipologia: Full text (versione editoriale)
Licenza: PUBBLICO - Pubblico con Copyright
Dimensione 69.69 kB
Formato Adobe PDF
69.69 kB Adobe PDF Visualizza/Apri

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2383593
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact